Stay updated on Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial

Sign up to get notified when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The page footer now shows Revision: v3.6.4, replacing v3.6.3. This indicates a minor software/version update with no changes to study details or how to participate.
    Difference
    0.1%
    Check dated 2026-07-25T18:03:35.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    No Change Detected
  5. Check
    32 days ago
    Change Detected
    Summary
    The page's revision label was updated from v3.6.2 to v3.6.3 in the footer. This represents a minor site version update and does not alter any study details or page content.
    Difference
    0.1%
    Check dated 2026-07-04T08:22:37.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    A new Revision tag shows v3.6.2 on the page, replacing v3.6.0, indicating a minor update to the page template or backend. No visible study information or actions appear to be changed.
    Difference
    0.1%
    Check dated 2026-06-27T06:43:42.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    Recruitment status on the study page now indicates 'No longer looking for participants', signaling that enrollment is closed. New help and navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study), and the Intervention/Treatment header formatting was standardized, accompanied by a revision note (Revision: v3.6.0).
    Difference
    0.6%
    Check dated 2026-06-13T04:40:54.000Z thumbnail image
  8. Check
    60 days ago
    Change Detected
    Summary
    Footer area updated to include a Moffitt Cancer Center Clinical Trials website link and the sponsor's institution name (H. Lee Moffitt Cancer Center and Research Institute), along with a 'Helpful Links Provided by' label. The page revision tag was updated from v3.5.4 to v3.5.5.
    Difference
    0.2%
    Check dated 2026-06-05T23:46:36.000Z thumbnail image
  9. Check
    67 days ago
    Change Detected
    Summary
    The deletions remove sponsor attribution blocks for the study (H. Lee Moffitt Cancer Center and Research Institute) and the reference to the Moffitt Clinical Trials website, as well as the 'Helpful Links Provided by' label. This changes how attribution and related navigation are presented on the page.
    Difference
    0.2%
    Check dated 2026-05-29T22:55:44.000Z thumbnail image

Stay in the know with updates to Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.